Original Title
Abbott acquiring Exact Sciences for $23 billion
Original Content
Global healthcare leader Abbott announced Thursday that it has reached a $23 billion deal to acquire Exact Sciences. Abbott is acquiring Exact Sciences for $23 billion, the global healthcare leader announced on Thursday. Exact Sciences shareholders will receive $105 per common share, totaling approximately $21 billion in equity value. The deal is expected to close in the second quarter of 2026, pending shareholder approval. According to a press release, the acquisition aims to enhance Abbott's presence in the cancer diagnostics segment. Shareholders of Exact Sciences will receive $105 per common share, representing a total equity value of approximately $21 billion under this agreement, with an estimated enterprise value of $23 billion. The acquisition is projected to generate more than $3 billion in revenue this year. Exact Sciences, a Madison-based company, focuses on early cancer detection and personalized treatments, leading in precision oncology and cancer screening, among other areas. “Together, the companies will accelerate innovation, expand access to life-changing diagnostics, and help more people detect and manage cancer at its earliest, most treatable stages,” said Abbott.
Summary
Abbott Abbott is set to acquire Exact Sciences Exact Sciences Corp. for $23 billion, with $105 per share and an expected close in Q2 2026, subject to approvals. The deal aims to strengthen Abbott’s cancer diagnostics footprint and is projected to generate over $3 billion in revenue this year.
Key Facts
- Deal value: $23 billion enterprise value; equity value around $21 billion.
- Offer: $105 per Exact Sciences share.
- Expected closing: Q2 2026, pending approvals.
- Focus: Strengthen cancer diagnostics and precision oncology capabilities.
“Together, the companies will accelerate innovation, expand access to life-changing diagnostics, and help more people detect and manage cancer at its earliest, most treatable stages,” said Abbott.
Author’s Note
Abbott is pursuing a strategic expansion in cancer diagnostics through a substantial acquisition, signaling a deeper commitment to precision oncology and early cancer detection.
*** Would you like this rewritten to a different HTML structure or adjusted for a particular publication style?More News
- Time to talk about Bruno! Brunno Ferreira defeats Marvin Vettori by Unanimous Decision
- UFC 323 Results
- Pearl Harbor Remembrance Day 2025 Remembers 84 Years
- Marvin Vettori “The Italian Dream”
- Newcastle 2-1 Burnley: Scott Parker post-match interview
- Durham Osteopathy Receives 2025 Consumer Choice Award
- Awareness walk held to commemorate INT'L Anti-Corruption Day
- Bridging Generations in B&NES to commemorate Holocaust Memorial Day 2026
- Analysis: Spirited response can't mask issues at both ends
- As Durham crime rates fall, city remains vigilant